Clinical Trial Update: Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating sintilimab with chidamide and azacitidine for refractory or relapsed peripheral T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Chidamide (chidamide)
• Sintilimab (sintilimab)

Snippet

Sponsor: Peking University | Conditions: Peripheral T-cell Lymphoma | Phase 2 | Status: UNKNOWN